Advertisement


Hans Gerdes, MD, on Endoscopic Therapies for Early-Stage Esophageal Cancers

2015 NCCN Annual Conference

Advertisement

Hans Gerdes, MD, of Memorial Sloan Kettering Cancer Center, discusses a new approach to the management of early-stage esophageal cancers with endoscopic resections.



Related Videos

Cost of Care
Health-Care Policy

Robert W. Carlson, MD, and Lee N. Newcomer, MD, MHA, on 20 Years of Improving Cancer Care Together: A Payer’s Perspective

Robert W. Carlson, MD, Chief Executive Officer of the National Comprehensive Cancer Network, and Lee N. Newcomer, MD, MHA, of UnitedHealthCare, discuss the value of NCCN Guidelines in determining coverage decisions, the future of affordable care, bundled payments, and the clear value approach.

Breast Cancer

Ingrid A. Mayer, MD, on New Therapies for Hormone-Sensitive Advanced Breast Cancer

Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discusses the evolution of endocrine therapy for metastatic breast cancer.

Cost of Care

Clifford Goodman, PhD, and Peter B. Bach, MD, MAPP, on Value-Based Decision-Making at the Bedside

Clifford Goodman, PhD, of the The Lewin Group, and Peter B. Bach, MD, MAPP, of Memorial Sloan Kettering Cancer Center, discuss the affordability of cancer care, the “financial toxicities” of high drug prices, and what could and should be done about it.

Colorectal Cancer

Axel Grothey, MD, on Optimizing Systemic Therapy Selection in Metastatic Colorectal Cancer

Axel Grothey, MD, of the Mayo Clinic Cancer Center, discusses how the NCCN Guidelines can help oncologists make strategic choices of the various agents available to treat metastatic colorectal cancer, individualizing patient care.

Skin Cancer
Symptom Management

Mario E. Lacouture, MD, on Management of Dermatologic Toxicities Associated With Targeted Therapies

Mario E. Lacouture, MD, of Memorial Sloan Kettering Cancer Center, discusses the effect on patients of dermatologic toxicities associated with targeted therapies: their psychosocial impact, financial burden, physiological pain, and potential to alter therapy. But the side effects of targeted treatments can and should be addressed.

Advertisement

Advertisement




Advertisement